Sharekhan

Emcure Pharmaceuticals Ltd

Wed 11/06/2025,15:55:42 | NSE : EMCURE

₹ 1368.3032.80 (2.46%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1326.80

Previous Close

₹ 1335.50

Volume

189930

Mkt Cap ( Rs. Cr)

₹25927.01

High

₹ 1384.50

Low

₹ 1326.80

52 Week High

₹ 1580.00

52 Week Low

₹ 889.00

Book Value Per Share

₹ 217.37

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Emcure Pharmaceuticals Ltd

Your Vote -

Buy

83.33%

Hold

0.00%

Sell

16.67%

83.33%

6 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

1368.30

1633

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

1633

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Emcure Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Emcure Pharmaceutica - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    3 Jun 2025, 7:31PM EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Trans
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Change in Management

    3 Jun 2025, 7:24PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Resignation of Senior Management Pers
  • Emcure Pharmaceutica - Cessation

    3 Jun 2025, 7:19PM Emcure Pharmaceuticals Limited has informed the Exchange regarding Cessation of Mr Anil Kothiyal as Other of the company w.e.f. Jun 06, 2025.
  • Emcure Pharmaceutica - Acquisition-XBRL

    2 Jun 2025, 8:22PM Emcure Pharmaceuticals Limited has informed the Exchange regarding Acquisition
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Acquisition

    2 Jun 2025, 8:21PM Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\Listing Regulations\), we would like to in
  • Emcure Pharmaceutica - Acquisition

    2 Jun 2025, 8:15PM Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    28 May 2025, 6:12PM The transcript of Earnings Call for Q4 FY 25 held on May 22, 2025 at 3:30 P.M. (IST)
  • Emcure Pharmaceutica - Analysts/Institutional Investor Meet/Con. Call Updates

    28 May 2025, 6:12PM Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
  • Emcure Pharmaceutica - Clarification On Volume Movement Letter

    27 May 2025, 1:56PM Clarification on Volume Movement Letter
  • Emcure Pharmaceutica - Clarification sought from Emcure Pharmaceuticals Ltd

    27 May 2025, 12:58PM The Exchange has sought clarification from Emcure Pharmaceuticals Ltd on May 27, 2025, with reference to Movement in Volume. <BR><BR>The reply is awai
  • Emcure Pharmaceutica - Copy of Newspaper Publication

    23 May 2025, 3:33PM Emcure Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    22 May 2025, 6:24PM Audio recording of Earnings Call - Q4 FY25
  • Emcure Pharmaceutica - Analysts/Institutional Investor Meet/Con. Call Updates

    22 May 2025, 6:21PM Emcure Pharmaceuticals Limited has informed the Exchange about Link of Recording
  • Emcure Pharmaceutica - Updates

    22 May 2025, 4:12PM Emcure Pharmaceuticals Limited has informed the Exchange regarding amendment of Code of Conduct for regulating, monitoring and reporting of Insider tr
  • Emcure Pharmaceutica - Incorporation-XBRL

    22 May 2025, 3:52PM Emcure Pharmaceuticals Limited has informed the Exchange regarding Incorporation
  • Emcure Pharmaceutica - General Updates

    22 May 2025, 3:46PM Emcure Pharmaceuticals Limited has informed the Exchange about Intimation of proposed incorporation of a Wholly-owned Subsidiary.
  • Emcure Pharmaceutica - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    22 May 2025, 3:23PM EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Trans
  • Emcure Pharmaceutica - General Updates

    22 May 2025, 3:22PM Emcure Pharmaceuticals Limited has informed the Exchange about appointment of Secretarial Auditors subject to approval of Members in the ensuing Annua
  • Emcure Pharmaceutica - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    22 May 2025, 3:06PM EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Trans
  • Emcure Pharmaceutica - Appointment

    22 May 2025, 3:04PM Emcure Pharmaceuticals Limited has informed the Exchange regarding Re-appointment of Mr Mukund Gurjar as Executive Director of the company w.e.f. Augu
  • Emcure Pharmaceutica - General Updates

    22 May 2025, 2:42PM Board of Directors at its meeting held today recommended the Final Dividend for FY 2024-25
  • Emcure Pharmaceutica - Outcome of Board Meeting-XBRL

    22 May 2025, 2:37PM Emcure Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on 22-May-2025 for Dividend
  • Emcure Pharmaceutica - Corporate Action-Board approves Dividend

    22 May 2025, 2:37PM Recommendation of Final Dividend for the financial year 2024-25
  • Emcure Pharmaceutica - Outcome of Board Meeting

    22 May 2025, 2:34PM Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Acquisition

    22 May 2025, 3:50PM Intimation of proposed incorporation of a Wholly-owned Subsidiary by the name \Emcure Generics Private Limited\
  • Emcure Pharmaceutica - Appointment Of Secretarial Auditor

    22 May 2025, 3:28PM Appointment of M/s. SVD & Associates, Company Secretaries in Practice, as the Secretarial Auditors of the Company, for a term of 5 (five) consecutive
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Change in Management

    22 May 2025, 3:11PM Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company.
  • Emcure Pharmaceutica Q4 net profit zooms 381.57% at Rs 139.56 cr

    22 May 2025, 2:52PM The company reported standalone net profit of Rs 139.56 crore for the quarter ended March 31, 2025 as compared to Rs 28.98 crore in the same period la
  • Emcure Pharmaceutica - Audited Financial Results For The Quarter And Year Ended March 31, 2025

    22 May 2025, 2:49PM Audited Financial Results for the quarter and year ended March 31, 2025
  • Emcure Pharmaceutica - Board Meeting Outcome for Outcome Of Board Meeting Held On May 22, 2025

    22 May 2025, 2:28PM Outcome of Board Meeting held on May 22, 2025:\r\n1. Audited Financial Results (standalone and consolidated) for the quarter and year ended March 31,
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 May 2025, 8:11PM Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
  • Emcure Pharmaceutica - Analysts/Institutional Investor Meet/Con. Call Updates

    13 May 2025, 8:07PM Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Emcure Pharmaceutica - Board Meeting Intimation

    13 May 2025, 7:49PM EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 22-May-2025 to consider and approve the Yearly Audited Fina
  • Emcure Pharmaceutica - Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For T

    13 May 2025, 7:38PM Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 ,inter alia, to consid
  • Emcure Pharmaceutica - Disclosure under SEBI Takeover Regulations

    12 May 2025, 1:00PM Satish Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu
  • Emcure Pharmaceutica has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    21 Apr 2025, 4:20PM As of March 2025, 77.92% is owned by Promoters and 22.08% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 77.69% and Fore
  • Emcure Pharmaceutica - Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulat

    18 Apr 2025, 5:10PM Announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\SEBI Listing Regulations\) - Update
  • Emcure Pharmaceutica - General Updates

    18 Apr 2025, 5:07PM Emcure Pharmaceuticals Limited has informed the Exchange about General Updates
  • Emcure Pharmaceutica - Updates

    18 Apr 2025, 5:01PM Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of change in email and website address of Registrar and Share Transfer
  • Emcure Pharmaceutica - Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent Of The Company

    18 Apr 2025, 4:57PM Intimation of change in email and website address of Registrar and Share Transfer Agent of the Company
  • Emcure Pharmaceutica - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2025, 4:26PM Confirmation Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025, r
  • Emcure Pharmaceutica - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2025, 4:14PM Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Tillomed acquires strategic pharma portfolio from Manx in &pound;19.7 million deal

    4 Apr 2025, 12:38PM Tillomed Laboratories Limited, the European subsidiary of Emcure Pharmaceuticals Ltd, has signed an Asset Purchase Agreement (APA) with UK-based Manx
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    4 Apr 2025, 12:16PM Please find enclosed herewith a Press Release titled \Emcure's European subsidiary Tillomed acquires strategic pharma portfolio from Manx.\
  • Emcure Pharmaceutica - Press Release

    4 Apr 2025, 12:12PM Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 04, 2025, titled ""Emcure s European subsidiary Tillome
  • Emcure Pharmaceutica - Press Release

    1 Apr 2025, 12:50PM Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2025, titled ""Emcutix and WiQo Sign Exclusive
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    1 Apr 2025, 12:52PM Please find enclosed herewith a Press Release titled \Emcutix and WiQo Signs Exclusive Licensing Partnership to revolutionize Derma-cosmetic Treatment
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    31 Mar 2025, 6:15PM Please find enclosed herewith a Press Release titled \Gennova Advances Pathbreaking AI-Enhanced saRNA Vaccine for one of the deadliest known viruses i
  • Emcure Pharmaceutica - Press Release

    31 Mar 2025, 6:12PM Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 31, 2025, titled ""Gennova Advances Pathbreaking
  • Emcure Pharmaceutica - Trading Window-XBRL

    25 Mar 2025, 6:17PM Emcure Pharmaceuticals Limited has informed the Exchange about Closure of Trading Window
  • Emcure Pharmaceutica - Trading Window

    25 Mar 2025, 6:04PM Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regula
  • Emcure Pharmaceutica - Alteration Of Capital and Fund Raising-XBRL

    24 Mar 2025, 7:57PM Emcure Pharmaceuticals Limited has informed the Exchange regarding Allotment of Securities
  • Emcure Pharmaceutica - Allotment of Securities

    24 Mar 2025, 7:51PM Emcure Pharmaceuticals Limited has informed the Exchange regarding allotment of 51500 securities pursuant to ESOP/ESPS at its meeting held on March 24
  • Emcure Pharmaceutica - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    24 Mar 2025, 7:49PM Intimation under Regulation 30 of SEBI Listing Regulations, 2015, for allotment of Equity Shares pursuant to exercise of ESOPs under the Emcure- Emplo
  • Emcure Pharma signs exclusive in-licensing agmt with WiQo

    1 Apr 2025 , 3:07PM Emcure Pharma signs exclusive in-licensing agmt with Italy-based WiQo for skin treatments
  • Emcure Pharmaceuticals signs royalty-free voluntary licensing agreement with Gilead

    3 Oct 2024 , 10:52AM Emcure Pharmaceuticals signs agreement with Gilead for the Manufacture and Global Supply of Lenacapavir

Key fundamentals

Evaluate the intrinsic value of Emcure Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 3680.183 3349.595 3509.625 3286.318 3607.34
Liabilities 3680.183 3349.595 3509.625 3286.318 3607.34
Equity 189.483 181.152 180.852 180.852 180.852
Gross Profit 646.837 441.894 438.492 794.671 743.405
Net Profit 317.128 160.834 160.062 446.811 420.475
Cash From Operating Activities 558.285 584.973 505.374 427.712 774.871
NPM(%) 7.23 4.59 5.15 13.19 13.33
Revenue 4381.924 3497.655 3107.086 3387.242 3153.664
Expenses 3735.087 3055.761 2668.594 2592.571 2410.259
ROE(%) 7.69 3.9 3.88 10.84 10.2

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
3 30 0 1167.7

Peers

Other companies within the same industry or sector that are comparable to Emcure Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 855.40 0.52 28.38 780.86 301.39 0.58
Lotus Eye Hospital and Institute Ltd 72.06 -1.95 205.89 2845.35 3.55 0.00
Vaishali Pharma Ltd 12.58 -2.25 209.67 1466.60 3.13 0.00
Astec Lifesciences Ltd 808.70 -0.33 0.00 2682.92 -687.10 0.00

Company Info

Our Company was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. Our Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of our Company and the certificate of incorporation of our Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, our Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of our Company was changed to `Emcure Pharmaceuticals Limited', pursuant to our Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.Major events and milestones:1981-Our Company was incorporated as Emcure Pharmaceuticals Private Limited1999-Amalgamation of Lasor Drugs Limited with our Company2001-Our Company was converted from a deemed public company into a public company-Amalgamation of Emcure Laboratories Private Limited, Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiralal Mehta Sales Private Limited with our Company.-Our Subsidiary, Gennova Biopharmaceuticals Limited was incorporated in India2002-Our Company received an approval to manufacture "S (-) Amlodipine Besilate tablets Asomex - 2.5" from the Joint Commissioner, Food and Drugs Administration, Pune, Maharashtra, India-Our Subsidiary, Zuventus Healthcare Limited, was incorporated in India2006-Blackstone GPV Capital Partners Mauritius V-C Ltd. subscribed to 226,325 Equity Shares of face value of ?10 each of our Company and 17,931,642 optionally convertible redeemable preference shares of our Company for the total investment of ?2,250 million.-Our Company established a facility at Kurkumbh, Pune, Maharashtra, India-Our Company commenced operations of injectables facility at Hinjawadi, Pune, Maharashtra, India2007-Facility established by our Subsidiary, Gennova at Hinjawadi, Pune, Maharashtra, India became operational-Our Subsidiary, Gennova received an approval from the Central Drugs Standard Control Organisation to start manufacturing "Recombinant Tissue Plasminogen Activator (TNK-t-PA)"-Our Subsidiary, Emcure Nigeria Limited, was incorporated in Nigeria2009-Our Company commenced production of tablets and capsules at our facility at Jammu, Jammu and Kashmir, India.2010-Our Subsidiary, Emcure Pharmaceuticals Mena FZ-LLC was incorporated in Dubai-Our Subsidiary, Emcure Pharmaceuticals South Africa (Pty) Ltd, was incorporated, in South Africa2011-Our Subsidiary, Emcure Brasil Farmaceutica LTDA, was incorporated, in Brazil2012-Our Company acquired rights of BICNU-Our Subsidiary, Emcure Pharma UK Ltd., was incorporated in the United Kingdom2014-BC Investments IV Limited acquired 13.09% of the then existing equity share capital of our Company (i.e., 5,918,386 Equity Shares of face value of ?10 each) from Blackstone GPV Capital Partners Mauritius V-C Ltd.-Our Subsidiary, Emcure UK acquired Tillomed Laboratories Limited-Our Subsidiary, Emcure Pharma Peru S.A.C., was incorporated in Peru-Our Subsidiary, Emcure Pharma Mexico S.A. DE C.V., was incorporated in Mexico-Our Subsidiary, Zuventus, obtained consent for establishment of industrial unit from Department of Commerce and Industries, Government of Sikkim, India2015-Our Company entered into Canada through acquisition of Marcan Pharmaceuticals Inc.-Our Subsidiary, Emcure Pharmaceuticals Pty Ltd., was incorporated in Australia2016-Tenecteplase (TNK - t - PA), manufactured by Gennova, approved for additional indication i.e., in thrombolytic treatment of the acute ischemic stroke within three hours of stroke initiation by the Directorate General of Health Services, CDSCO - Biological Division, Government of India-Our Subsidiary, Emcure UK acquired Bhardwaj Pharma GmbH (now known as Tillomed Pharma GmbH)-Our, Subsidiary Emcure UK acquired Laboratorios Tillomed Spain SLU2017-Our Subsidiary, Zuventus, established a manufacturing facility at Bengaluru, Karnataka, India-Our Subsidiary, Tillomed Italia S.R.L, was incorporated in Italy2018-Our Company received a license to work a factory in relation to the manufacturing facility situated at Sanand, Gujarat, India.-Our Subsidiary, Tillomed France S.A.S., was incorporated in France2020-Our Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile2021-Our Subsidiary, Lazor Pharmaceuticals Limited, was incorporated in Kenya-Our Subsidiary, Emcure Pharma Philippines Inc., was incorporated in Philippines2022-Our Subsidiary, Tillomed Malta Ltd, was incorporated in Malta2023-Our Subsidiary, Marcan Pharmaceuticals Inc., acquired Mantra Pharma Inc

Our Company was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. Our Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of our Company and the certificate of incorporation of our Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, our Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of our Company was changed to `Emcure Pharmaceuticals Limited', pursuant to our Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.Major events and milestones:1981-Our Company was incorporated as Emcure Pharmaceuticals Private Limited1999-Amalgamation of Lasor Drugs Limited with our Company2001-Our Company was converted from a deemed public company into a public company-Amalgamation of Emcure Laboratories Private Limited, Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiralal Mehta Sales Private Limited with our Company.-Our Subsidiary, Gennova Biopharmaceuticals Limited was incorporated in India2002-Our Company received an approval to manufacture "S (-) Amlodipine Besilate tablets Asomex - 2.5" from the Joint Commissioner, Food and Drugs Administration, Pune, Maharashtra, India-Our Subsidiary, Zuventus Healthcare Limited, was incorporated in India2006-Blackstone GPV Capital Partners Mauritius V-C Ltd. subscribed to 226,325 Equity Shares of face value of ?10 each of our Company and 17,931,642 optionally convertible redeemable preference shares of our Company for the total investment of ?2,250 million.-Our Company established a facility at Kurkumbh, Pune, Maharashtra, India-Our Company commenced operations of injectables facility at Hinjawadi, Pune, Maharashtra, India2007-Facility established by our Subsidiary, Gennova at Hinjawadi, Pune, Maharashtra, India became operational-Our Subsidiary, Gennova received an approval from the Central Drugs Standard Control Organisation to start manufacturing "Recombinant Tissue Plasminogen Activator (TNK-t-PA)"-Our Subsidiary, Emcure Nigeria Limited, was incorporated in Nigeria2009-Our Company commenced production of tablets and capsules at our facility at Jammu, Jammu and Kashmir, India.2010-Our Subsidiary, Emcure Pharmaceuticals Mena FZ-LLC was incorporated in Dubai-Our Subsidiary, Emcure Pharmaceuticals South Africa (Pty) Ltd, was incorporated, in South Africa2011-Our Subsidiary, Emcure Brasil Farmaceutica LTDA, was incorporated, in Brazil2012-Our Company acquired rights of BICNU-Our Subsidiary, Emcure Pharma UK Ltd., was incorporated in the United Kingdom2014-BC Investments IV Limited acquired 13.09% of the then existing equity share capital of our Company (i.e., 5,918,386 Equity Shares of face value of ?10 each) from Blackstone GPV Capital Partners Mauritius V-C Ltd.-Our Subsidiary, Emcure UK acquired Tillomed Laboratories Limited-Our Subsidiary, Emcure Pharma Peru S.A.C., was incorporated in Peru-Our Subsidiary, Emcure Pharma Mexico S.A. DE C.V., was incorporated in Mexico-Our Subsidiary, Zuventus, obtained consent for establishment of industrial unit from Department of Commerce and Industries, Government of Sikkim, India2015-Our Company entered into Canada through acquisition of Marcan Pharmaceuticals Inc.-Our Subsidiary, Emcure Pharmaceuticals Pty Ltd., was incorporated in Australia2016-Tenecteplase (TNK - t - PA), manufactured by Gennova, approved for additional indication i.e., in thrombolytic treatment of the acute ischemic stroke within three hours of stroke initiation by the Directorate General of Health Services, CDSCO - Biological Division, Government of India-Our Subsidiary, Emcure UK acquired Bhardwaj Pharma GmbH (now known as Tillomed Pharma GmbH)-Our, Subsidiary Emcure UK acquired Laboratorios Tillomed Spain SLU2017-Our Subsidiary, Zuventus, established a manufacturing facility at Bengaluru, Karnataka, India-Our Subsidiary, Tillomed Italia S.R.L, was incorporated in Italy2018-Our Company received a license to work a factory in relation to the manufacturing facility situated at Sanand, Gujarat, India.-Our Subsidiary, Tillomed France S.A.S., was incorporated in France2020-Our Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile2021-Our Subsidiary, Lazor Pharmaceuticals Limited, was incorporated in Kenya-Our Subsidiary, Emcure Pharma Philippines Inc., was incorporated in Philippines2022-Our Subsidiary, Tillomed Malta Ltd, was incorporated in Malta2023-Our Subsidiary, Marcan Pharmaceuticals Inc., acquired Mantra Pharma Inc

Read More

Parent Organisation

Emcure Pharmaceuticals Ltd.

Founded

16/04/1981

Managing Director

Mr.Satish Ramanlal Mehta

NSE Symbol

EMCUREEQ

FAQ

The current price of Emcure Pharmaceuticals Ltd is ₹ 1368.30.

The 52-week high for Emcure Pharmaceuticals Ltd is ₹ 1384.50 and the 52-week low is ₹ 1326.80.

The market capitalization of Emcure Pharmaceuticals Ltd is currently ₹ 25927.01. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Emcure Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Emcure Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Emcure Pharmaceuticals Ltd shares.

The CEO of Emcure Pharmaceuticals Ltd is Mr.Satish Ramanlal Mehta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT